Tech

La vendita allo scoperto per Bio-Techne dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Bio-Techne. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Bio-Techne (NASDAQ:TECH) Azioni, Report sulle vendite allo scoperto

Bio-Techne

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Corp

EVOLVE FANGMA INDEX UNHDGD ETF

Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Bio-Techne to report an earnings per share (EPS) of $0.38.
Investors in Bio-Techne are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 3.4% increase in the share price the next day.
Here's a look at Bio-Techne's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.45</td>
<td>0.41</td>
<td>0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.48</td>
<td>0.40</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>3.0%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730210492_0_0.png" alt="eps graph" />
<h3>Analyst Insights on Bio-Techne</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Bio-Techne.
Analysts have provided Bio-Techne with 3 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $82.33, suggesting a potential 16.98% upside.
<h3>Comparing Ratings with Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Medpace Hldgs, Charles River and Bio-Rad Laboratories, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Medpace Hldgs received a Neutral consensus from analysts, with an average 1-year price target of $380.62, implying a potential 440.81% upside.</li>
<li>As per analysts' assessments, Charles River is favoring an Neutral trajectory, with an average 1-year price target of $200.92, suggesting a potential 185.48% upside.</li>
<li>Bio-Rad Laboratories is maintaining an Neutral status according to analysts, with an average 1-year price target of $378.4, indicating a potential 437.65% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for Medpace Hldgs, Charles River and Bio-Rad Laboratories are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio-Techne</td>
<td>Buy</td>
<td>1.59%</td>
<td>$203.35M</td>
<td>1.99%</td>
</tr>
<tr>
<td>Medpace Hldgs</td>
<td>Neutral</td>
<td>8.29%</td>
<td>$169.01M</td>
<td>11.72%</td>
</tr>
<tr>
<td>Charles River</td>
<td>Neutral</td>
<td>-3.19%</td>
<td>$353.71M</td>
<td>2.44%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>Neutral</td>
<td>-6.26%</td>
<td>$355.12M</td>
<td>-27.36%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Bio-Techne ranks highest in revenue growth among its peers. It also leads in gross profit margin. However, it has the lowest return on equity compared to its peers.
<h3>Get to Know Bio-Techne Better</h3>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
<h3>Bio-Techne's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Bio-Techne's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 1.59%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bio-Techne's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Bio-Techne's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.99% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bio-Techne's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/TECH/earnings">To track all earnings releases for Bio-Techne visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

TECH

A Look Ahead: Bio-Techne's Earnings Forecast

News

Bio-techne Corporation In Collaboration With ScaleReadyAnd CellReady Announced That ImmunoScape Won A G-rex Grant

A significant insider transaction involving the exercise of company stock options was reported on September 16, by John L Higgins, Director at Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), as per the latest SEC filing.
What Happened: A notable Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000842023/000106299324016642//Archives/edgar/data/842023/000106299324016642/0001062993-24-016642-index.htm">U.S. Securities and Exchange Commission</a> revealed that Higgins, Director at Bio-Techne, exercised stock options for 6,000 shares of TECH, resulting in a transaction value of $310,860.
Bio-Techne shares are trading down 0.0% at $74.76 at the time of this writing on Tuesday morning. Since the current price is $74.76, this makes Higgins's 6,000 shares worth $310,860.
<h3>Delving into Bio-Techne's Background</h3>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
<h3>Financial Milestones: Bio-Techne's Journey</h3>
Revenue Growth: Bio-Techne displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.59%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 66.43%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Bio-Techne's EPS reflects a decline, falling below the industry average with a current EPS of 0.26.
</li>
</ul>
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 71.2 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 10.37 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 38.73 reflects market recognition of Bio-Techne's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes Worth Your Attention</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000842023">Check Out The Full List Of Bio-Techne's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Witnessing An Insider Decision, John L Higgins Exercises Options Valued At $310K At Bio-Techne

Health Care

General

ScaleReady And Bio-Techne Launched The G-Rex Optimized ProPak GMP Cytokines, Ideally Tailored To High-Efficiency Closed System Cell And Gene-modified Cell Therapy Manufacturing

In the last three months, 4 analysts have published ratings on Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bio-Techne, presenting an average target of $83.0, a high estimate of $95.00, and a low estimate of $70.00. This current average reflects an increase of 0.4% from the previous average price target of $82.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1723561239_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Bio-Techne by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$85.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Techne. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Techne's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TECH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bio-Techne analyst ratings.</a>
<h2>All You Need to Know About Bio-Techne</h2>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
<h3>Bio-Techne's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Bio-Techne showcased positive performance, achieving a revenue growth rate of 0.88% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Bio-Techne's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.26% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.99%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bio-Techne's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average at 0.2, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings)

Benchmark analyst Robert Wasserman reiterates Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and maintains $95 price target.

Price Target

Reiteration

Benchmark Reiterates Buy on Bio-Techne, Maintains $95 Price Target

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) shares decreased 12.06% after reporting worse-than-expected <a href="https://www.benzinga.com//node/40232820" target="_blank" rel="noreferrer noopener">first-quarter FY25 sales results</a>. Analysts revised <a href="https://www.benzinga.com/quote/mck/analyst-ratings" target="_blank" rel="noreferrer noopener">the company&#8217;s price targets</a>.</li>
<li>BIO-TECHNE Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) stock 11.71% value last week on worse-than-expected Q4 revenue results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) stock declined 10.62% following weak <a href="https://www.benzinga.com//node/40234107" target="_blank" rel="noreferrer noopener">second-quarter financial results</a>. Several analysts updated their ratings <a href="https://www.benzinga.com//node/40264035" target="_blank" rel="noreferrer noopener">and price targets on the stock</a>.</li>
<li>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares dipped 10.41% on Q2 results and cut its FY24 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener">adjusted outlook</a>. Analysts lowered the <a href="https://www.benzinga.com/quote/crl/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock fell 9.33% on worse-than-expected Q2 sales results. The company issued FY25 net product revenue guidance below estimates, and several analysts <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener">cut their price forecasts</a> for the stock.</li>
<li>Monster Beverage Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) stock plummeted 8.95% after the company reported <a href="https://www.benzinga.com//node/40233200" target="_blank" rel="noreferrer noopener">Q2 financial results</a>. Many analysts <a href="https://www.benzinga.com/quote/mnst/analyst-ratings" target="_blank" rel="noreferrer noopener">cut the price target</a>.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock dived 8.93% following worse-<a href="https://www.benzinga.com//node/40182863" target="_blank" rel="noreferrer noopener">than-expected quarterly results</a>. Several analysts lowered the price <a href="https://www.benzinga.com/quote/bld/analyst-ratings" target="_blank" rel="noreferrer noopener">target on the company</a>.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) stock dived 7.01% after the company reported worse-than-expected quarterly EPS results and issued <a href="https://www.benzinga.com//node/40203008" target="_blank" rel="noreferrer noopener">third-quarter revenue guidance below estimates</a>. Many analysts slashed the <a href="https://www.benzinga.com//node/40227192" target="_blank" rel="noreferrer noopener">price target and forecast on the stock</a>.</li>
<li>Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) stock fell 6.94% <a href="https://www.benzinga.com//node/40246477" target="_blank" rel="noreferrer noopener">following a quarterly earnings miss</a>.</li>
<li>SBA Communications Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) stock fell 6.85% in the last week.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40303526/shopify-palantir-and-uber-are-among-top-10-large-cap-gainers-last-week-aug-4-aug-10-are-the-others-i" target="_blank" rel="noreferrer noopener">Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Large Cap

Movers

ABNB

DELL

MNST

SBAC

SMCI

SRPT

Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?

RBC Capital analyst Conor McNamara maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Sector Perform and lowers the price target from $72 to $70.

RBC Capital Maintains Sector Perform on Bio-Techne, Lowers Price Target to $70

Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Outperform and raises the price target from $81 to $82.

Baird Maintains Outperform on Bio-Techne, Raises Price Target to $82

WIIM

Bio-Techne shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) reported quarterly earnings of $0.49 per share which met the analyst consensus estimate. The company reported quarterly sales of $306.098 million which missed the analyst consensus estimate of $306.491 million by 0.13 percent. This is a 1.59 percent increase over sales of $301.320 million the same period last year.

Earnings Misses

Bio-Techne Q4 2024 Adj. EPS $0.49, Inline, Sales $306.098M Miss $306.491M Estimate

Bio-Techne Announced The Launch Of The Leo System Which Offers Higher Throughput, Flexibility, And Efficiency Over The Current Jess And Abby Simple Western Systems

Bio-techne Announced Its Participation In Spear Bio's $45M Series A Funding Round, Spear Bio Will Use The Proceeds To Further Accelerate Product Development And Scale Its In-house Manufacturing Capacity

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$10.00</td>
<td>$382.5K</td>
<td>31</td>
<td>5.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.00</td>
<td>$42.1K</td>
<td>50.0K</td>
<td>3.9K</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$75.00</td>
<td>$44.5K</td>
<td>2.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>TECH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$85.00</td>
<td>$190.0K</td>
<td>157</td>
<td>1.0K</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$310.00</td>
<td>$38.5K</td>
<td>129</td>
<td>950</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$62.50</td>
<td>$26.7K</td>
<td>1.3K</td>
<td>926</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/30/24</td>
<td>$160.00</td>
<td>$99.0K</td>
<td>677</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$40.00</td>
<td>$25.8K</td>
<td>4.3K</td>
<td>688</td>
</tr>
<tr>
<td>PRCT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$55.00</td>
<td>$42.3K</td>
<td>89</td>
<td>205</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$660.00</td>
<td>$234.6K</td>
<td>519</td>
<td>203</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding SMMT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>), we observe a put option trade with bearish sentiment. It expires in 56 day(s) on September 20, 2024. Parties traded 1700 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $382.5K, with a price of $225.0 per contract. There were 31 open contracts at this strike prior to today, and today 5035 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bullish sentiment. It expires in 175 day(s) on January 17, 2025. Parties traded 1500 contract(s) at a $40.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $42.1K, with a price of $28.0 per contract. There were 50053 open contracts at this strike prior to today, and today 3954 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option trade that happens to be bearish, expiring in 56 day(s) on September 20, 2024. This event was a transfer of 100 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $44.5K, with a price of $445.0 per contract. There were 2754 open contracts at this strike prior to today, and today 1237 contract(s) were bought and sold. 
• For TECH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), we notice a call option trade that happens to be bullish, expiring in 21 day(s) on August 16, 2024. This event was a transfer of 1000 contract(s) at a $85.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $190.0 per contract. There were 157 open contracts at this strike prior to today, and today 1051 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 21 day(s) on August 16, 2024. This event was a transfer of 107 contract(s) at a $310.00 strike. This particular put needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $38.5K, with a price of $360.0 per contract. There were 129 open contracts at this strike prior to today, and today 950 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option sweep that happens to be neutral, expiring in 56 day(s) on September 20, 2024. This event was a transfer of 100 contract(s) at a $62.50 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $26.7K, with a price of $266.0 per contract. There were 1373 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be neutral, expiring in 35 day(s) on August 30, 2024. This event was a transfer of 233 contract(s) at a $160.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $99.0K, with a price of $425.0 per contract. There were 677 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option trade with bullish sentiment. It expires in 539 day(s) on January 16, 2026. Parties traded 20 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $25.8K, with a price of $1290.0 per contract. There were 4375 open contracts at this strike prior to today, and today 688 contract(s) were bought and sold. 
• Regarding PRCT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), we observe a put option sweep with bullish sentiment. It expires in 84 day(s) on October 18, 2024. Parties traded 55 contract(s) at a $55.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $42.3K, with a price of $770.0 per contract. There were 89 open contracts at this strike prior to today, and today 205 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 175 day(s) on January 17, 2025. Parties traded 190 contract(s) at a $660.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $234.6K, with a price of $1235.0 per contract. There were 519 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

GILD

PRCT

SMMT

10 Health Care Stocks Whale Activity In Today's Session

Highlighted on July 10, it was unveiled in an SEC filing that Higgins, Director at Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000842023/000106299324013645//Archives/edgar/data/842023/000106299324013645/0001062993-24-013645-index.htm">U.S. Securities and Exchange Commission</a>, Higgins, Director at Bio-Techne, exercised stock options for 6,000 shares of TECH. The transaction value amounted to $300,960.
Bio-Techne shares are trading up 3.99% at $74.94 at the time of this writing on Thursday morning. Since the current price is $74.94, this makes Higgins's 6,000 shares worth $300,960.
<h3>Delving into Bio-Techne's Background</h3>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
<h3>Bio-Techne: Financial Performance Dissected</h3>
Positive Revenue Trend: Examining Bio-Techne's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.16% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 67.43%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Bio-Techne's EPS is below the industry average. The company faced challenges with a current EPS of 0.31. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average. With a ratio of 0.25, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 57.66 is lower than the industry average, implying a discounted valuation for Bio-Techne's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.06 is above industry norms, reflecting an elevated valuation for Bio-Techne's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 32.53, Bio-Techne demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000842023">Check Out The Full List Of Bio-Techne's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

John L Higgins At Bio-Techne Capitalizes: Options Exercised, Resulting In $300K

4 analysts have shared their evaluations of Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.75, with a high estimate of $95.00 and a low estimate of $81.00. This current average reflects an increase of 8.54% from the previous average price target of $79.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1716386456_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Bio-Techne is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bio-Techne. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bio-Techne compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bio-Techne's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Bio-Techne's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TECH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bio-Techne analyst ratings.</a>
<h2>About Bio-Techne</h2>
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
<h3>Understanding the Numbers: Bio-Techne's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Bio-Techne's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 3.16%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.17%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bio-Techne's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.47% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bio-Techne's ROA stands out, surpassing industry averages. With an impressive ROA of 1.8%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average. With a ratio of 0.25, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Bio-Techne: Insights From 4 Analyst Reviews

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) from Buy to Neutral and announces $85 price target.

Downgrades

Citigroup Downgrades Bio-Techne to Neutral, Announces $85 Price Target

Biotech

Contracts

RGLS

Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. ((a Bio-Techne group company, NASDAQ:<a href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) both be revoked; (2) that Advanced Cell Diagnostics' infringement claims against Molecular Instruments are dismissed; and (3) that Advanced Cell Diagnostics make a costs payment of £1.35 million (approximately $1.72 million at the current exchange rate) to Molecular Instruments.
In a 2022 lawsuit filed at the High Court of England and Wales (proceedings no. HP-2022-000026), Advanced Cell Diagnostics alleged that Molecular Instruments' HCR&#x2122; RNA-ISH technology infringed European Patents (UK) 2,500,439 and 1,910,572. Mr. Justice Meade handed down a judgment on April 23, 2024 finding that both patents are invalid on grounds of obviousness based on "overwhelming" primary evidence (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcaselaw.nationalarchives.gov.uk%2Fewhc%2Fpat%2F2024%2F898%3Fquery%3Dmolecular%2Binstruments&amp;esheet=54005528&amp;newsitemid=20240521591985&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcaselaw.nationalarchives.gov.uk%2Fewhc%2Fpat%2F2024%2F898&amp;index=1&amp;md5=10972006a50db5eac0491a3af6d3552f">https://caselaw.nationalarchives.gov.uk/ewhc/pat/2024/898</a>).

Legal

Molecular Instruments Announced The Patents Court Of England And Wales Has Ordered That Two Patents Owned By Advanced Cell Diagnostics, A Bio-Techne Company, Both Be Revoked, Advanced Cell Diagnostics' Infringement Claims Against Molecular Instruments Are Dismissed And Advanced Cell Diagnostics Make A Costs Payment Of ~$1.72M To Molecular Instruments

These large-cap stocks were the best performers in the last week amid earnings season. Are they in your portfolio?
<ol>
<li>Carvana Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) shares escalated 39.1% after it reported Q1 revenue of&nbsp;$3.061 billion, which beat the&nbsp;consensus&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38566697" rel="noreferrer noopener">estimate&nbsp;of&nbsp;$2.673 billion</a>. Several analysts&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38594906" rel="noreferrer noopener">raised their forecasts</a>.</li>
<li>NIO Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares jumped 21.5% after the&nbsp;company's&nbsp;April&nbsp;vehicle deliveries increased&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38547416" rel="noreferrer noopener">134.6%&nbsp;year-over-year</a>.</li>
<li>Paramount Global&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) shares surged 21.5% after it reported first-quarter&nbsp;revenue of&nbsp;$7.685 billion, which missed the&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38503655" rel="noreferrer noopener">consensus estimate of&nbsp;$7.732 billion</a>. The company said CEO&nbsp;Bob Bakish&nbsp;is stepping down from the studio. Paramount reportedly got a $26 billion acquisition offer from&nbsp;Sony Group Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) and&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38598651" rel="noreferrer noopener">Apollo Global Management, Inc.</a><a target="_blank" href="https://www.benzinga.com//node/38598651" rel="noreferrer noopener">&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>)</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) shares rose 20.0% after it reported first-quarter sales of $5.37 billion — beating the consensus of $5.15 billion — and also <a href="https://www.benzinga.com//node/38523582" target="_blank" rel="noreferrer noopener">raised the FY24 outlook</a>. Multiple firms raised their <a href="https://www.benzinga.com/quote/THC/analyst-ratings" target="_blank" rel="noreferrer noopener">respective price targets on the stock</a>.</li>
<li>Pinterest, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) shares increased 19.9% after the company reported&nbsp;first-quarter&nbsp;revenue of&nbsp;$740 million, which beat the&nbsp;consensus estimate&nbsp;of&nbsp;$699.872 million and a loss per share of $0.04, which beat analyst estimates&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38534719" rel="noreferrer noopener">for a loss of $0.09 per share</a>. Several analysts raise&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38558198" rel="noreferrer noopener">forecasts&nbsp;on the stock</a>.</li>
<li>Bio-Techne Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) increased 17.2% following upbeat Q3 quarterly results and the announcement of a distribution <a href="https://www.benzinga.com//node/38544446" target="_blank" rel="noreferrer noopener">agreement with Thermo Fisher Scientific</a>.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) shares were up 14.9%  after the company reported better-than-expected Q1 revenue of $1.82 billion, beating the consensus of $1.736 billion, and adjusted EPS stood at $0.57, <a href="https://www.benzinga.com//node/38591577" target="_blank" rel="noreferrer noopener">beating the consensus of $0.52</a>. Few analysts raised the <a href="https://www.benzinga.com/quote/HWM/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Garmin Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) shares grew 13.9% after it reported&nbsp;first-quarter&nbsp;FY24 revenue of&nbsp;$1.38 billion, beating the&nbsp;consensus of&nbsp;$1.25 billion and proforma EPS of&nbsp;$1.42&nbsp;beat&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38552073" rel="noreferrer noopener">the&nbsp;consensus of&nbsp;$1.01</a>.&nbsp;Some analysts raised&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GRMN/analyst-ratings" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares are up 12.5% after it reported sales of $167 million, beating the consensus of $97.5 million, and reported <a href="https://www.benzinga.com//node/38592653" target="_blank" rel="noreferrer noopener">smaller-than-expected Q1 losses</a>.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares are up 12.5%. The company reported better-than-expected <a href="https://www.benzinga.com//node/38498046" target="_blank" rel="noreferrer noopener">first-quarter results last Thursday</a>. </li>
<li>Woodward, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) shares increased 11.2% after&nbsp;the company reported&nbsp;better-than-expected&nbsp;Q2&nbsp;financial results and&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38502107" rel="noreferrer noopener">raised&nbsp;FY24 guidance</a>.</li>
<li>KE Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) shares are up 9.7%.</li>
<li>JD.Com, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) shares grew 9.2%.</li>
<li>Amcor Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) shares gained 9.1%.</li>
<li>Mobileye Global Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares rose 8.9%.</li>
</ol>
See Also: <a href="https://www.benzinga.com/24/05/38633879/last-weeks-worst-performing-stocks-are-these-15-large-cap-stocks-in-your-portfolio-april-28-may-4-20">Last Week&#8217;s Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)</a>
Photo: Shutterstock

Equities

AMCR

BEKE

CVNA

GRMN

MBLY

MRNA

PARAA

PINS

SNAP

Sony Group Corporation American Depositary Shares

SONY

Which Large-Cap Stocks Are Winning This Earnings Season? 15 Stocks To Watch (April 28-May 4, 2024)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Techne (TECH – Research Report), Pediatrix Med...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Pediatrix Medical Group (MD) and Arcus Biosciences (RCUS)

Invesco Health Care Fund Q2 2024 Review

AMR Update - Mid-2024

In a report released today, Sung Ji Nam from Scotiabank maintained a Buy rating on Bio-Techne (TECH – Research Report), with a price target of $83....

Scotiabank Reaffirms Their Buy Rating on Bio-Techne (TECH)

Analyst Catherine Ramsey Schulte of Robert W. Baird maintained a Buy rating on Bio-Techne (TECH – Research Report), retaining the price target of $...

Optimistic Growth and Improved Financial Outlook for Bio-Techne: A Buy Recommendation

Columbia Acorn Fund Q2 2024 Investment Commentary

BofA's global contenders and defenders list

Conestoga Capital Advisors Q3 2024 Quarterly Commentary

RBC Capital analyst Conor McNamara maintained a Hold rating on Bio-Techne (TECH – Research Report) on October 23 and set a price target of $77.00. ...

Comments

Bio-Techne

Vendite allo scoperto

Bio-Techne (NASDAQ:TECH) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO